Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 13256-13258
10.1182/blood-2022-158197